Vivo Capital, a California-based investment firm which backs healthcare companies in the U.S. and Greater China, has rounded up over US$1.28 billion for its ninth private equity fund, Vivo Capital Fund IX LP, according to the company’s latest regulatory filing with the SEC.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription? Log in
